ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Dendritic cells"

  • Abstract Number: 2078 • ACR Convergence 2025

    Neutrophil Extracellular Traps from Patients with Idiopathic Inflammatory Myopathies Induce Interferogenic Responses in Macrophages and Myeloid Dendritic Cells

    Yatzil Reyna Juárez1, Jennifer Tiaré Balderas Miranda2, Beatriz Alcalá Carmona3, María José Ostos Prado4, karina santana5, Diana Gómez-Martín6 and Jiram Torres Ruiz7, 1Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, 2Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, 3INCMNSZ, Cdmx, Distrito Federal, Mexico, 4Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, 5INCMNSZ, Ciudad de México, Federal District, Mexico, 6INCMNSZ, Mexico city, Federal District, Mexico, 7INCMNSZ, Mexico, Federal District, Mexico

    Background/Purpose: Dermatomyositis (DM) and anti-synthetase syndrome (AS) are idiopathic inflammatory myopathies (IIM) with perifascicular pathology involving vasculopathy, macrophages, dendritic cells and an overexpression of interferon-stimulated…
  • Abstract Number: 1852 • ACR Convergence 2025

    Cellular Landscape of Cutaneous Lupus Erythematosus Revealed by Single-Cell RNA Sequencing and Spatial Transcriptomics in the Lupus Accelerating Medicine Partnership Cohort

    Victoria Werth1, Jun Kang2, Lais Lopes Almeida Gomes3, Christopher Richardson4, Benjamin Chong5, J. Michelle Kahlenberg6, Joel Guthridge7, Wade DeJager8, Susan Macwana7, Caleb Marlin7, Judith James7, Rachael Bogle9, Alex Tsoi9 and Johann Gudjonsson6, 1University of Pennsylvania, Wynnewood, PA, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3University of Pennsylvania, Philadelphia, PA, 4University of Rochester Medical Center, Rochester, NY, 5University of Texas Southwestern Medical Center, Dallas, TX, 6University of Michigan, Ann Arbor, MI, 7Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Oklahoma Medical Research Foundation, Oklahoma City, 9University of Michigan, Holland, OH

    Background/Purpose: Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease associated with systemic lupus erythematosus (SLE) and characterized by a prominent type I interferon…
  • Abstract Number: 1538 • ACR Convergence 2025

    Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277

    Minoru Hasegawa1, Jun Kinoshita2, Shigeki Otsubo3, Kana Yamada3 and Ehsanollah Esfandiari4, 1Division of Medicine, University of Fukui, Yoshida-gun, Fukui, Japan, 2Kyowa Kirin Co., Ltd., Chiyoda-ku, Tokyo, Japan, 3Kyowa Kirin Co., Ltd., Tokyo, Japan, 4Kyowa kirin International plc, London, United Kingdom

    Background/Purpose: Plasmacytoid dendritic cells (pDCs) are known to be the main source of type 1 interferon (IFN), which is the cause of various autoimmune diseases.…
  • Abstract Number: 0952 • ACR Convergence 2025

    Therapeutic Potential of PaPE-1 in Reducing TLR7-Mediated Inflammation in a Murine Model of Lupus

    Rachael Werner1, Jena Wirth1, Gary Gilkeson1 and Melissa Cunningham2, 1Medical University of South Carolina, Charleston, SC, 2Medical University of SC, Charleston, SC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that disproportionately affects women, underscoring the critical role of sex chromosomes and sex hormones—particularly estrogen—in…
  • Abstract Number: 0948 • ACR Convergence 2025

    Presentation of Apoptotic Cell-Derived Autoantigens in Systemic Autoimmune Disease

    Lance Peterson1, Hannah KL De Cleene2, Cheryl Lichti2, David Bending3 and Kodi Ravichandran2, 1Rheumatology and Immunology, Pediatrics, Washington University School of Medicine, St. Louis, MO, 2Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, 3Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, United Kingdom

    Background/Purpose: Systemic lupus erythematosus is a chronic, multisystem autoimmune disease characterized by the dysregulated clearance of dying cells, which results in the release of damage-associated…
  • Abstract Number: 0916 • ACR Convergence 2025

    UVB-Irradiated Keratinocyte Extracellular Vesicles Trigger Innate Immune Activation via Type I Interferons and STING Pathway

    Ahmed Eldaboush1, Darae Kang2 and Victoria Werth3, 1Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Potomac, MD, 3University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Extracellular vesicles (EVs) are cell-derived nanoparticles that mediate cell-cell communication. EVs are implicated in photosensitive autoimmune diseases like dermatomyositis (DM) and systemic lupus (SLE),…
  • Abstract Number: 0863 • ACR Convergence 2025

    Myeloid Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells

    Raphael Kirou1, Iago Pinal-Fernandez1, Maria Casal-Dominguez1, Katherine Pak1, Chiseko Ikenaga2, Christopher Nelke3, Stefania Dell'orso1, Faiza Naz1, Shamima Islam1, Gustavo Gutierrez-Cruz1, Werner Stenzel4, Albert Selva-O'Callaghan5, José Milisenda6 and Andrew Mammen7, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2The University of Tokyo, Tokyo, Japan, 3Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, 4Charite University, Berlin, Germany, 5Hospital Universitari Vall d'Hebron, Barcelona, Spain, 6Hospital Clinic de Barcelona, Barcelona, Spain, 7NIH, Bethesda, MD

    Background/Purpose: Although inclusion body myositis (IBM) is an inflammatory myopathy, there are no effective immunomodulating agents, underlying the need for better understanding of its pathogenesis.…
  • Abstract Number: 0800 • ACR Convergence 2025

    Microbiota-Derived Indole Promotes Collagen-Induced Arthritis Type-17 Immunity through Intestinal Dendritic Cell Cytokine Production

    Jing Jing Li1, Sucai Liu2, Brenda Seymour3, Brendan Allen2, Le Yiphyo2, Cassandra Levens1 and Kristine Kuhn4, 1Rheumatology, Aurora, CO, 2University of Colorado School of Medicine, Aurora, CO, 3University of Colorado School of Medicine, Denver, CO, 42022 - 2023 / Adult/ University of Colorado, Aurora, CO

    Background/Purpose: One of the most substantial impacts of microbe-host interactions at the intestinal mucosa is the development of type 17 immunity. A Th17 signature has…
  • Abstract Number: 0482 • ACR Convergence 2025

    R-2487, a Synthetic Biology-Based Oral Immunotherapy, Promotes Treg-Mediated Immune Rebalancing and Reduces Disease Activity in Rheumatoid Arthritis Patients

    Christian Furlan Freguia1, Janet Stephens1, Sathya Janardhanan1, Chuck Bourne1, Kaitlyn Skeie1, Hudson Lowe1, David Pascual2 and Gary Fanger1, 1Rise Therapeutics, Rockville, MD, 2University of Wyoming, Laramie, WY

    Background/Purpose: R-2487 is a novel, orally delivered, synthetic biology-based immunotherapy that utilizes Lactococcus lactis as a carrier vehicle to deliver Colonization Factor Antigen I (CFA/I)…
  • Abstract Number: 0060 • ACR Convergence 2024

    Spectral Cytometry Shows Increased CD56hi NK Cells and New HLA-DR+CD56+ Phenotypes in RA

    Estelle Khairallah1, Haani Qudsi2, Jihad Ben Gabr1, Andras Perl3 and Christian Geier1, 1SUNY Upstate Medical University, Syracuse, NY, 2Norton College of Medicine, Syracuse, NY, 3SUNY, Syracuse, NY

    Background/Purpose: Previous studies of RA patients have shown changes in NK cell populations (as defined by CD56 expression). The nature of these cellular changes remains…
  • Abstract Number: 0067 • ACR Convergence 2024

    Psoriasis Patients at Risk for Psoriatic Arthritis Have Increased Levels of Circulating Pro-migratory Dendritic Cells

    Shashank Cheemalavagu, Unnikrishnan Chandrasekharan, Oliver Wessely, Uyen Tran and M. Elaine Husni, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Early diagnosis of Psoriatic Arthritis (PsA) is critical for timely intervention to prevent poor clinical outcomes. Despite well-known clinical predictors of PsA, the mechanisms…
  • Abstract Number: 0071 • ACR Convergence 2024

    Stage-Specific Roles of Interleukin-23/Interleukin-17 Axis and Type 1 Regulatory T Cells Dynamics in Axial Spondyloarthritis

    Jina Yeo1, Min-Gang Kim2, Hee Sung Kwon3, Mi Ryoung Seo1, Hyo-Jin Choi1, YunJae Jung4, Eun Young Lee5 and Han Joo Baek6, 1Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, 2Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, 4Department of Microbiology, College of Medicine, Gachon University, Incheon, Republic of Korea, 53Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, 6Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Inchon, South Africa

    Background/Purpose: The interleukin (IL)-23/IL-17 pathway is central to axial spondyloarthritis (axSpA) pathogenesis, yet treatments targeting IL-23 show inconsistent effectiveness across spondyloarthritis subtypes. We hypothesized that…
  • Abstract Number: 0072 • ACR Convergence 2024

    The Association Between Activation of Inflammasome and HLA-B27 in Dendritic Cells of Patients with Axial Spondyloarthritis

    Jina Yeo1, Min-Gang Kim2, Hye Eun Lee3, Yeonsoo Yang2, Mi Ryoung Seo1, Hyo-Jin Choi1, Eun Young Lee4, Dae Ho Lee3 and Han Joo Baek5, 1Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, 2Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea, 3Division of Endocrinology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, 43Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, 5Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Inchon, South Africa

    Background/Purpose: Axial spondyloarthritis (axSpA) exhibits a predominant involvement of the innate immune system, marked by abnormal functions of innate immune cell such as dendritic cells…
  • Abstract Number: 0962 • ACR Convergence 2024

    Characterizing the Contribution of Myeloid Cells to Limited and Diffuse Cutaneous Systemic Sclerosis

    Parker Jones1, Salina Dominguez2, Miranda Gurra3, Gaurav Gadhvi4, Tyler Therron2, Kathleen Aren5, Carla Cuda3, Monique Hinchcliff6, Harris Perlman3, Hadijat Makinde3 and Deborah Winter7, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Northwestern University, Chicago, 3Northwestern University, Chicago, IL, 4University of Michigan, Ann Arbor, MI, 5Northwestern University Division of Rheumatology, Chicago, IL, 6Yale School of Medicine, Westport, CT, 7Northwestern University, Skokie, IL

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by multiorgan fibrosis. The two main subtypes are diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc…
  • Abstract Number: 1542 • ACR Convergence 2024

    Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus

    Arezou Khosroshahi1, Sarah Welsh2, Liangwei Wang2, David Larson2 and Nisha Jain2, 1Emory University, Atlanta, GA, 2Amgen, Inc., Rockville, MD

    Background/Purpose: SLE, an autoimmune disease affecting multiple organ systems, is characterized by periods of flares and remission. Type I interferon secreted at high levels by…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology